Combined treatment with TZM intraperitoneally and PARP inhibitor intracranially increases survival of tumor-bearing mice.

Animals (14 per group) were inoculated intracranially with L5178Y lymphoma cells (day 0). Treatment was performed by intracranial injection of NU1025 (1 mg/mouse) or intraperitoneal injection of TZM (100 mg/kg) on day 2 after tumor challenge. An additional dose of TZM was administered on day 3. Control animals (CTR) were treated with drug vehicles only (ie, intracranial polyethylene glycol + intraperitoneal dimethyl sulfoxide) on day 2. Combined treatment with intracranial NU1025 and TZM (100 mg/kg) twice significantly increased survival of tumor-bearing mice with respect to control or TZM-treated groups (P < .0001). Differences between survival curves of mice treated with TZM or NU1025 and survival curve of controls were not statistically significant.